BriaCell Accepts Letter Of Intent From Weill Cornell Medicine Outlining Plans To Initiate A Clinical Trial Of Bria-IMT In High-Risk Early-Stage Triple Negative Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
BriaCell has accepted a letter of intent from Weill Cornell Medicine to initiate a clinical trial of Bria-IMT in high-risk early-stage triple negative breast cancer.
August 31, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BriaCell's acceptance of the letter of intent from Weill Cornell Medicine to initiate a clinical trial of Bria-IMT could potentially boost the company's profile and stock value.
The initiation of a new clinical trial for Bria-IMT in high-risk early-stage triple negative breast cancer could potentially lead to positive outcomes for BriaCell. This could increase investor confidence and drive up the stock price of BCTX in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100